Literature DB >> 19932428

Thrombopoietin and platelet production in chronic immune thrombocytopenia.

David J Kuter1, Terry B Gernsheimer.   

Abstract

Since 1968, a greater understanding of platelet biology and its regulation by thrombopoietin (TPO) has emerged. It is now recognized that immune thrombocytopenic purpura (ITP) is a disorder of reduced platelet production as well as increased platelet destruction. New therapies for ITP have emerged that have exploited this new pathophysiologic understanding. This article reviews the biology of TPO, the regulation of its circulating level in ITP, the platelet kinetic data supporting inappropriate platelet production in ITP, and the TPO mimetic agents available to treat ITP.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19932428      PMCID： PMC2789970          DOI： 10.1016/j.hoc.2009.09.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  77 in total

1.  Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.

Authors:  Robert McMillan; Lei Wang; Aaron Tomer; Janet Nichol; Jeanne Pistillo
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

2.  A Rapid Method for the Differential Staining of Blood Films and Malarial Parasites.

Authors:  J H Wright
Journal:  J Med Res       Date:  1902-01

Review 3.  Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.

Authors:  David J Kuter; C Glenn Begley
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

4.  Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies.

Authors:  N R Shulman; V J Marder; R S Weinrach
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

5.  High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.

Authors:  J L Villeval; K Cohen-Solal; M Tulliez; S Giraudier; J Guichard; S A Burstein; E M Cramer; W Vainchenker; F Wendling
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

6.  Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP).

Authors:  I Branehög; J Kutti; A Weinfeld
Journal:  Br J Haematol       Date:  1974-05       Impact factor: 6.998

7.  Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.

Authors:  L T Goodnough; D J Kuter; J McCullough; S J Slichter; J DiPersio; J Romo; R Peterson; K J Smith; T Raife; D Tomita; S Armstrong
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

8.  The platelet destruction site in thrombocytopenic purpuras.

Authors:  Y Najean; N Ardaillou; C Dresch; J Bernard
Journal:  Br J Haematol       Date:  1967-05       Impact factor: 6.998

Review 9.  Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.

Authors:  David J Kuter
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

10.  Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.

Authors:  W S Alexander; A W Roberts; N A Nicola; R Li; D Metcalf
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113
View more
  9 in total

1.  Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.

Authors:  Muna Iraqi; Jose Perdomo; Feng Yan; Philip Y-I Choi; Beng H Chong
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 2.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

3.  Identification of a new Mpl-interacting protein, Atp5d.

Authors:  Hongyan Liu; Zhenhu Zhao; Yuxu Zhong; Yajun Shan; Xiaohong Sun; Bingzhi Mao; Yuwen Cong
Journal:  Mol Cell Biochem       Date:  2014-03-11       Impact factor: 3.396

4.  Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children.

Authors:  Natalia Maximova; D Zanon; F Rovere; A Maestro; G Schillani; R Paparazzo
Journal:  Int J Hematol       Date:  2015-06-18       Impact factor: 2.490

Review 5.  Pathophysiology and management of primary immune thrombocytopenia.

Authors:  Hirokazu Kashiwagi; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

6.  IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans.

Authors:  J Bayry; A Aouba; A Nguyen; Y Repesse; M Ebbo; Y Allenbach; O Benveniste; J M Vallat; L Magy; S Deshayes; G Maigné; H de Boysson; A Karnam; S Delignat; S Lacroix-Desmazes
Journal:  Clin Exp Immunol       Date:  2021-02-22       Impact factor: 4.330

7.  Evaluating the Role of Janus Kinase Pathways in Platelet Homeostasis Using a Systems Modeling Approach.

Authors:  Sarita Koride; Satyaprakash Nayak; Christopher Banfield; Mark C Peterson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-06-25

8.  Sialic acid and platelet count regulation: Implications in immune thrombocytopenia.

Authors:  Melissa M Lee-Sundlov; Leonardo Rivadeneyra; Hervé Falet; Karin M Hoffmeister
Journal:  Res Pract Thromb Haemost       Date:  2022-04-08

Review 9.  The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer development and metastasis.

Authors:  Gerd Bendas; Martin Schlesinger
Journal:  Exp Hematol Oncol       Date:  2022-04-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.